A study of 11 drugs now in clinical trials suggests they do kill cancer cells—but through a different mechanism than indicated in previous research.

The 2019 Lasker medical and research awards celebrate advances in scientists’ understanding of T and B cells, Herceptin antibodies for treating breast cancer, and vaccine coverage around the globe.

Despite a solid understanding of the biological basis of fragile X syndrome, researchers have struggled to develop effective treatments.

The US Food and Drug Administration green lights a therapy for an extreme form of multidrug resistant TB.

Novartis, which bought the biotech firm in 2018, announced that the company’s top scientists have left, and news reports say it’s because they were involved in using manipulated data to get the gene therapy Zolgensma approved.

Our resident bacteria can affect the activity of immunotherapies and other medicines in the body.

There are currently more than two dozen ongoing Phase 1 and Phase 2 trials using different vaccine platforms such as DNA, RNA, synthetic long peptides, and dendritic cells.

Through their effects on metabolism and immunity, bacteria in the gut affect whether medications will be effective for a given patient.

Five independent groups got different results in a drug-response experiment, despite sharing protocols, reagents, and cell lines. The researchers identify technical variables that could be to blame.